EC
TVTX icon

EntryPoint Capital’s Travere Therapeutics TVTX Stock Holding History

EntryPoint Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,351
Closed -$243K – 925
2025
Q4 		$243K Sell
6,351
-5,750
-48% -$187K 0.09% 458
2025
Q3 		$289K Sell
12,101
-6,337
-34% -$119K 0.11% 383
2025
Q2 		$273K Sell
18,438
-710
-4% -$11.8K 0.14% 327
2025
Q1 		$343K Sell
19,148
-1,452
-7% -$29.5K 0.16% 256
2024
Q4 		$359K Buy
+20,600
New +$364K 0.15% 260
2024
Q3 		– Sell
-20,444
Closed -$168K – 1343
2024
Q2 		$168K Buy
20,444
+16,343
+399% +$110K 0.08% 500
2024
Q1 		$31.6K Buy
+4,101
New +$34.6K 0.03% 937

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EntryPoint Capital's TVTX Position: Q1 2026 in Review

EntryPoint Capital sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 6,351 shares — an estimated $243K sold.

EntryPoint Capital first reported a position in TVTX in Q1 2024 and held it in 7 quarters. The position peaked at $359K in Q4 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • EntryPoint Capital reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EntryPoint Capital sold 6,351 Travere Therapeutics shares in Q1 2026, an estimated $243K.
  • EntryPoint Capital first reported a position in Travere Therapeutics in Q1 2024 and held it in 7 quarters.
  • EntryPoint Capital's Travere Therapeutics position peaked at $359K in Q4 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.